2023

Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma
Beishuizen A, Mellgren K, Andrés M, Auperin A, Bacon C, Bomken S, Burke G, Burkhardt B, Brugieres L, Chiang A, Damm-Welk C, d'Amore E, Horibe K, Kabickova E, Khanam T, Kontny U, Klapper W, Lamant L, Le Deley M, Loeffen J, Macintyre E, Mann G, Meyer-Wentrup F, Michgehl U, Minard-Colin V, Mussolin L, Oschlies I, Patte C, Pillon M, Reiter A, Rigaud C, Roncery L, Salaverria I, Simonitsch-Klupp I, Uyttebroeck A, Verdu-Amoros J, Williams D, Woessmann W, Wotherspoon A, Wrobel G, Zimmermann M, Attarbaschi A, Turner S
LANCET HAEMATOL. 2023;10(3):e213-e224.

2022

Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials?
Damm-Welk C, Lovisa F, Contarini G, Lüdersen J, Carraro E, Knörr F, Förster J, Zimmermann M, Sala A, Vinti L, Tondo A, Pillon M, Woessmann W, Mussolin L
CANCERS. 2022;14(7):.

Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia
Möker P, Zur Stadt U, Zimmermann M, Alawi M, Mueller S, Finger J, Knörr F, Riquelme A, Oschlies I, Klapper W, Bradtke J, Burkhardt B, Woessmann W, Damm-Welk C
LEUKEMIA. 2022;36(9):2343-2346.

2021

Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target
Larose H, Prokoph N, Matthews J, Schlederer M, Högler S, Alsulami A, Ducray S, Nuglozeh E, Fazaludeen F, Elmouna A, Ceccon M, Mologni L, Gambacorti-Passerini C, Hoefler G, Lobello C, Pospisilova S, Janikova A, Woessmann W, Damm-Welk C, Zimmermann M, Federova A, Malone A, Smith O, Wasik M, Inghirami G, Lamant L, Blundell T, Klapper W, Merkel O, Burke G, Mian S, Ashankyty I, Kenner L, Turner S
HAEMATOLOGICA. 2021;106(6):1693-1704.

Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma
Liang H, Costanza M, Prutsch N, Zimmerman M, Gurnhofer E, Montes-Mojarro I, Abraham B, Prokoph N, Stoiber S, Tangermann S, Lobello C, Oppelt J, Anagnostopoulos I, Hielscher T, Pervez S, Klapper W, Zammarchi F, Silva D, Garcia K, Baker D, Janz M, Schleussner N, Fend F, Pospíšilová Š, Janiková A, Wallwitz J, Stoiber D, Simonitsch-Klupp I, Cerroni L, Pileri S, de Leval L, Sibon D, Fataccioli V, Gaulard P, Assaf C, Knörr F, Damm-Welk C, Woessmann W, Turner S, Look A, Mathas S, Kenner L, Merkel O
NAT COMMUN. 2021;12(1):.

Minimal Disease Monitoring in Pediatric Non-Hodgkin's Lymphoma: Current Clinical Application and Future Challenges
Mussolin L, Damm-Welk C, Pillon M, Woessmann W
CANCERS. 2021;13(8):.

2020

Quantification of minimal disseminated disease by quantitative PCR and digital PCR for NPM-ALK as prognostic factor in children with anaplastic large cell lymphoma
Damm-Welk C, Kutscher N, Zimmermann M, Attarbaschi A, Schieferstein J, Knörr F, Oschlies I, Klapper W, Woessmann W
HAEMATOLOGICA. 2020;105(8):2141-2149.

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial
Mussolin L, Le Deley M, Carraro E, Damm-Welk C, Attarbaschi A, Williams D, Burke A, Horibe K, Nakazawa A, Wrobel G, Mann G, Csóka M, Uyttebroeck A, Fernández-Delgado Cerdá R, Beishuizen A, Mellgren K, Burkhardt B, Klapper W, Turner S, D'Amore E, Lamant L, Reiter A, Woessmann W, Brugières L, Pillon M
CANCERS. 2020;12(10):.

2019

Minimal Disseminated and Minimal Residual Disease in Pediatric Non-Hodgkin Lymphoma
Mussolin L, Damm-Welk C, Wößmann W
2019. Non-Hodgkin´s Lymphoma in Children and Adolescence. Abla O, Attarbaschi A (Hrsg.). 1. Aufl. Cham: Springer, 119 - 129.

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
Singh V, Werner S, Schwalm S, Lennerz V, Ruf S, Stadler S, Hackstein H, Reiter A, Wölfel T, Damm-Welk C, Woessmann W
ONCOIMMUNOLOGY. 2019;8(9):e1625688.

Letzte Aktualisierung aus dem FIS: 19.04.2024 - 00:38 Uhr